Delayed versus immediate surgery following short-course neoadjuvant radiotherapy in resectable (T3N0/N+) rectal cancer.
Esra Kaytan-Saglam, Emre Balik, Sezer Saglam...
https://pubmed.ncbi.nlm.nih.gov/28374169/Actively Recruiting
Led by Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria · Updated on 2024-04-16
340
Participants Needed
14
Research Sites
208 weeks
Total Duration
Researchers are investigating the impact of the timing of minimally invasive surgery after neoadjuvant chemoradiotherapy for rectal cancer. This multicenter, randomized controlled trial aims to determine whether delaying surgery from the standard 8 weeks to 12 weeks influences the pathological complete response pCR, disease-free survival DFS, and overall survival OS in patients with locally advanced rectal cancer. The trial also explores the quality of life QoL outcomes related to these treatment intervals. Participants are randomly assigned to one of two groups one undergoes minimally invasive surgery, including robotic-assisted or standard laparoscopic procedures, 8 weeks after chemoradiation, and the other 12 weeks after. The trial includes surgeries such as low anterior resection, intersphincteric resection, or abdominoperineal resection using various robotic systems or standard laparoscopic methods. The study involves a recruitment period of 5 years with follow-up continuing for 5 years after the last patient is randomized. During the study, patients will complete questionnaires and undergo preoperative assessments including CT-scan and MRI to confirm tumor staging. Researchers will monitor outcomes including pathological response, survival rates, and quality of life. Patients provide informed consent and are evaluated for eligibility before randomization, which occurs near the start of neoadjuvant treatment. Safety and treatment effects are tracked throughout the study period, which may last up to 10 years including follow-up.
CONDITIONS
Timing to Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer
I
Igor Monsellato, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 to 12 weeks
Participants undergo neoadjuvant chemoradiotherapy followed by minimally invasive surgery either after 8 weeks or 12 weeks from chemoradiation treatment.
1 baseline visit and surgery visit
Duration - Up to 5 years
Participants are monitored for disease-free survival and overall survival outcomes up to 5 years after surgery.
Periodic visits during follow-up as per standard care
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Esra Kaytan-Saglam, Emre Balik, Sezer Saglam...
https://pubmed.ncbi.nlm.nih.gov/28374169/Igor Monsellato, Filippo Alongi, Elisa Bertocchi...
https://pubmed.ncbi.nlm.nih.gov/31842784/Fausto Petrelli, Giovanni Sgroi, Enrico Sarti...
https://pubmed.ncbi.nlm.nih.gov/24263329/Jérémie H Lefevre, Laurent Mineur, Salma Kotti...
https://pubmed.ncbi.nlm.nih.gov/27432930/Johan Erlandsson, Torbjörn Holm, David Pettersson...
https://pubmed.ncbi.nlm.nih.gov/28190762/Rolf Sauer, Heinz Becker, Werner Hohenberger...
https://pubmed.ncbi.nlm.nih.gov/15496622/Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Lead Sponsor